A step towards predicting checkpoint inhibitor response in kidney cancer

Affiliations

¹ Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
² Department of Radiation Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, USA; Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
³ Division of Medical Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
⁴ Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. Electronic address: spal@coh.org.

Free article

Comment

Manuel Caitano Maia et al. Lancet Oncol. 2017 Aug.

Free article

. 2017 Aug;18(8):982-983.

doi: 10.1016/S1470-2045(17)30533-8. Epub 2017 Jul 26.

¹ Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
² Department of Radiation Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, USA; Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
³ Division of Medical Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
⁴ Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. Electronic address: spal@coh.org.

No abstract available

Comment on

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, Wong YNS, Rowan A, Kanu N, Al Bakir M, Chambers T, Salgado R, Savas P, Loi S, Birkbak NJ, Sansregret L, Gore M, Larkin J, Quezada SA, Swanton C. Turajlic S, et al. Lancet Oncol. 2017 Aug;18(8):1009-1021. doi: 10.1016/S1470-2045(17)30516-8. Epub 2017 Jul 7. Lancet Oncol. 2017. PMID: 28694034